Formycon Announces Financial Year 2025 Results and Investor Conference Schedule

Formycon AG plans to publish its financial year 2025 results on April 22, 2026, with a conference call scheduled for the same day at 3:00 PM CEST. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during this event. The conference call will be broadcast live on the internet, and participants can register at https://webcast.meetyoo.de/reg/lNibT8TVWubG. After registration, participants will receive confirmation with individual dial-in data. The presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will be available for analysts' questions. The conference call will be recorded and can subsequently be accessed via the Formycon website at https://www.formycon.com/en/investor-relations/publications/.

Representatives of the Management Board will attend several international investor conferences in the second quarter of 2026, demonstrating the company's commitment to engaging with the investment community. These events include the Equity Forum Spring Conference in Frankfurt on May 11-12, 2026, featuring CFO Enno Spillner. The company will publish its first quarter 2026 results on May 28, 2026, with a conference call and webcast featuring CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. Additional conferences include the Jefferies Global Healthcare Conference in New York City on June 2-4, 2026, with CFO Enno Spillner; the mwb research Roundtable webcast on June 8, 2026, featuring the full management team; the Annual General Meeting in Munich on June 10, 2026; and the UBS Life Sciences Conference in London on June 18, 2026, with CFO Enno Spillner. The company's current events can be found at https://www.formycon.com/en/investors/financial-calendar/.

This announcement matters because Formycon operates in the rapidly growing biosimilars market, which analysts project could reach over 74 billion US dollars by 2030. The company's financial results and investor conference participation provide crucial insights into its performance and strategic direction as it navigates this expanding sector. With biosimilars expected to address patent expirations affecting blockbuster drugs worth more than 200 billion US dollars by 2032, Formycon's developments have significant implications for healthcare accessibility and cost reduction. The company currently has two biosimilars on the market, FYB201/ranibizumab and FYB202/ustekinumab, with FYB203/aflibercept approved by regulatory authorities and four pipeline candidates in development, including FYB208/dupilumab. These products target key therapeutic areas such as ophthalmology, immunology, and immuno-oncology, positioning Formycon to capitalize on market opportunities while contributing to patient access to affordable medicines. The scheduled investor engagements underscore the company's transparency and proactive communication strategy, which is essential for maintaining investor confidence in a competitive pharmaceutical landscape. As Formycon continues to develop and commercialize biosimilars, its financial performance and strategic initiatives will influence both healthcare systems and investment markets, making these announcements particularly significant for stakeholders monitoring the biosimilars industry's evolution.